Live Chat

Risperdal Overprescribed to Children is Linked to Socio-economic Status

 Children diagnosed with attention-deficit/hyperactivity disorder (ADHD) and other disruptive behavior disorders, who are publicly insured by Medicaid, were typically prescribed Risperdal more often than those not in a lower income socio-economic group. Even though Risperdal was not approved by the United States Food and Drug Administration (FDA) for ADHD, it was prescribed for an average of 180 days to youth between the ages of two and seventeen who were on Medicaid. This group of adolescents was much greater than those not on a public insurance plan. In addition, a large group of these youth were at some point in foster care and due to their socio-economical status were provided Medicaid.

As a result, many of the boys prescribed Risperdal have developed breasts and in some cases required surgery to have the breasts removed.

Legal Commentary 

From a civil standpoint, our firm has represented numerous individuals and families who have become victim to Risperdal’s dangerous side effects and the following psychological trauma. If you or a loved one have taken Risperdal and have experienced abnormal breast growth or milk production we encourage you to consult with one of our Risperdal attorneys as soon as possible. A successful civil claim pursued against the responsible party will ensure the victims are not burdened with costly medical expenses, and will hopefully compensate them for their pain, suffering, and lost wages for time missed from work. Further questions can be directed to the Fears | Nachawati Law Firm by emailing the lead Risperdal lawyer, Majed Nachawati at, or by calling our office at 1.866.705.7584.


About the Author

Majed Nachawati is a preeminent Pharmaceutical Products Liability Lawyer with a focus on representing Risperdal victims and families harmed by dangerous treatments on a nationwide basis. Mr. Nachawati has resolved numerous cases through trial and settlement that have resulted in seven and eight figure confidential settlements. He is on the Grievance Committee for the State Bar of Texas. He is licensed to practice before the Supreme Court of Texas and Arkansas, and is in most federal courts in the nation and holds specific licenses in the Northern, Southern, and Eastern Districts of Texas. Mr. Nachawati is a member of the Board of Directors of the Texas Trial Lawyers Association, the Board of Directors for Public Justice, a Leaders’ Forum and PAC member of the American Association for Justice. Mr. Nachawati has been recognized as a Super Lawyer in Texas Monthly Magazine for the past four consecutive years for legal excellence, in connection with pharmaceutical injury cases. Mr. Nachawati is also a member of The Million Dollar Advocates Forum. Mr. Nachawati can be reached by email at or by calling 1.866.705.7584.​

Drug Litigation